MODERNA, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Moderna, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).
MODERNA, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Moderna, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”).
Master Collaboration and License Agreement by and between MODERNA THERAPEUTICS, INC. and MERCK SHARP & DOHME CORP. January 12, 2015Collaboration and License Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York
This Master Collaboration and License Agreement (this “Agreement”), dated as of January 12, 2015 (the “Effective Date”), is made by and between Moderna Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Moderna”), and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”). Each of Moderna and Merck may be referred to herein as a “Party” or together as the “Parties”.
Amended and Restated Option Agreement by and between ModernaTx, Inc., and AstraZeneca AB June 15, 2018Option Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Option Agreement (this “A&R Option Agreement”) is made on the Amendment Effective Date by and between ModernaTx, Inc., a Delaware corporation (“Moderna”) and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”). Each of Moderna and AstraZeneca may be referred to herein as a “Party” or together as the “Parties.”
Patent Sublicense AgreementPatent Sublicense Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.
